Skip to main content
. 2015 Jun 15;33(21):2353–2360. doi: 10.1200/JCO.2015.60.9271

Fig 3.

Fig 3.

Disease-free survival (DFS) and overall survival (OS) hazard ratios (HRs) and 95% CIs for weekly paclitaxel (P1) and docetaxel every 3 weeks (D3) compared with paclitaxel every 3 weeks (P3) in overall population (A, B) and in patients with triple-negative breast cancer (TNBC) and hormone receptor–positive/human epidermal growth factor receptor 2–nonoverexpressing disease (HR+; C, D), including the prior report and current report.